Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Ontozry

Ontozry 12.5 mg tablets Ontozry 25 mg film-coated tablets Ontozry 50 mg film-coated tablets Ontozry 100 mg film-coated tablets Ontozry 150 mg film-coated tablets Ontozry 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8

HOS-146943 · Präparat HOS-099586

lamotrigine Depending on individual ↓ lamotrigine plasma response, the dose of concentrations cenobamate may need to be increased. Pharmacometric analyses of data from healthy subjects and Based on subpopulation patients showed that analyses of patients taking concomitant administration of concomitant lamotrigine, in cenobamate with lamotrigine individual cases, higher doses had no effect on cenobamate (200 - 400 mg/day) of exposures, but resulted in dose- cenobamate may be required dependent decreases in for efficacy. lamotrigine concentrations (by -21%, -35%, and -52% for cenobamate 100, 200, and 400 mg/day). carbamazepine No clinically meaningful ↓ carbamazepine plasma decreases in efficacy were concentrations observed in patients taking concomitant carbamazepine. In a study in healthy subjects, No dose adjustments are concomitant administration of required for both cenobamate 200 mg once daily carbamazepine and and carbamazepine 200 mg cenobamate. twice daily showed no significant change in exposure of cenobamate, but 7  carbamazepine exposures were slightly reduced (Cmax reduced by 23%, AUC reduced by 24%). Valproic acid No dose adjustments of No clinically relevant effect of cenobamate or valproic acid valproic acid are required. In a study in healthy subjects, concomitant administration of cenobamate 150 mg once daily and valproic acid 1,000 mg once daily showed no significant changes in exposures of either medicinal product. Pharmacometric analyses of data from healthy subjects and patients indicated that concomitant administration of cenobamate with valproic acid did not affect cenobamate exposures and had no clinically relevant reductions in valproic acid concentration. lacosamide, levetiracetam No dose adjustments are No clinically relevant effect of and oxcarbazepine required for cenobamate, lacosamide, levetiracetam and lacosamide, levetiracetam, or oxcarbazepine oxcarbazepine. Pharmacometric analyses of data from healthy subjects and patients indicated that concomitant administration with lacosamide, levetiracetam, or oxcarbazepine did not affect the exposure of cenobamate, and cenobamate did not have a clinically relevant effect on exposures of lacosamide, levetiracetam, or oxcarbazepine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproic acid (HOS-088515) carbamazepine (HOS-085618) lacosamide (HOS-119434) oxcarbazepine (HOS-110224) levetiracetam (HOS-090742)